Phase 3
N=230
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
Depressive Disorder, Major
Bottom Line
View on ClinicalTrials.gov: NCT03097133 ↗Enrolled (actual)
230
Serious AEs
4.9%
Results posted
Sep 2020
Primary outcome: Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase — -12.4; -15.7 units on a scale — p=0.006
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Esketamine (Drug); Placebo (Drug); Standard of Care (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Janssen Research & Development, LLC
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase |
-12.4; -15.7 | 0.006 sig |
| PRIMARY Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase |
-1.0; -1.0 | — |
| SECONDARY Number of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase |
4; 12; 12; 25; 20; 26 | — |
| SECONDARY Change From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase |
-8.2; -12.2; -12.4; -16.0; -15.7; -17.7 | — |
| SECONDARY Change From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase |
-1.0; -1.0; -1.0; -1.0; -2.0; -2.0 | — |
| SECONDARY Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase |
20; 38; 35; 36; 51; 52 | — |
| SECONDARY Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase |
0.0; -1.0; -1.0; -1.0; -2.0; -2.0 | — |
| SECONDARY Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase |
-6.3; -6.1; -7.0; -8.0 | — |
| SECONDARY Change From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase |
-9.0; -11.8; -15.1; -15.0; -15.3; -18.8 | — |
| SECONDARY Change From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase |
9.7; 13.4; 17.6; 21.4; 18.6; 27.0 | — |
| SECONDARY Change From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase |
0.129; 0.160; 0.194; 0.202; 0.194; 0.235 | — |
| SECONDARY Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase |
-2.5; -3.5; -5.2; -5.1; -5.5; -6.3 | — |
| SECONDARY Treatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase |
55.3; 63.5; 54.8; 68.8; 77.2; 71.3 | — |
| SECONDARY Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase |
-1.0; -1.0; -1.0; -1.0; -1.0; -1.0 | — |
| SECONDARY Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase |
-1.0; -1.0; -1.0; -1.0; -2.0; -2.0 | — |
| SECONDARY Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase |
87; 104 | — |
| SECONDARY Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase |
2; 2; 0; 0; 0; 0 | — |
| SECONDARY Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase |
1; 1; 0; 0; 0; 0 | — |
| SECONDARY Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase |
9; 2; 3; 2; 2; 2 | — |
| SECONDARY Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase |
2; 3 | — |
| SECONDARY Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase |
2; 1; 11; 12; 5; 2 | — |
| SECONDARY Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase |
0; 4; 3; 21; 20; 65 | — |
| SECONDARY Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase |
28; 106; 21; 86; 16; 75 | — |
Summary
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
Eligibility Criteria
Inclusion Criteria
- Participant must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI)
- Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?] AND Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI
- In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to participant's imminent risk of suicide
- Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (>) 28 predose on Day 1
- As part of standard of care treatment, participant agrees to be hospitalized voluntarily for a recommended period of 14 days after randomization (may be shorter or longer if clinically warranted in the investigator's opinion) and take prescribed non-investigational antidepressant therapy(ies) for at least the duration of the double-blind treatment phase (Day 25)
Exclusion Criteria
- Participant has a current DSM-5 diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder
- Participant currently meets DSM-5 criteria for borderline personality disorder. Note: Participant not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded
- Participant has a current clinical diagnosis of autism, dementia, or intellectual disability
- Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features
- Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, (except for nicotine or caffeine), within the 12 months before Screening. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
- Participant has a history or current signs and symptoms of liver or renal insufficiency, clinically significant cardiac (including unstable coronary artery disease and congestive heart failure, tachyarrhythmias and recent myocardial infarction) or vascular, pulmonary, gastrointestinal, endocrine (including uncontrolled hyperthyroidism), neurologic (including current or past history of seizures except uncomplicated childhood febrile seizures with no sequelae), hematologic, rheumatologic, or metabolic (including severe dehydration/ hypovolemia) disease
- Participant has known allergies, hypersensitivity, intolerance or contraindications to esketamine or ketamine or its excipients
Data sourced from ClinicalTrials.gov (NCT03097133). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.